Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.78 |
| ▸ | GRM5 | P41594 | 11/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523838 | 0.87 | HDAC6 (1.00) | HDAC6GRM5HPGDALDH1A1L3MBTL1 | |
| SCHEMBL2524047 | 0.85 | HDAC6 (0.70) | HDAC6GRM5HPGDALDH1A1L3MBTL1 | |
| SCHEMBL2522947 | 0.81 | HDAC6 (0.88) | HDAC6GRM5HPGDALDH1A1L3MBTL1 | |
| SCHEMBL12307491 | 0.79 | HDAC6 (0.64) | HDAC6GRM5HPGDALDH1A1L3MBTL1 | |
| SCHEMBL2521563 | 0.76 | HDAC6 (0.65) | HDAC6GRM5HPGDALDH1A1LMNA | |
| SCHEMBL25412001 | 0.76 | GRM5 (0.46) | HDAC6GRM5CYP4F2CYP4A11 | |
| SCHEMBL16309488 | 0.76 | GRM5 (0.66) | HDAC6GRM5HPGD | |
| SCHEMBL20631562 | 0.74 | HPGD (0.86) | HPGDALDH1A1L3MBTL1GAAMEN1 | |
| SCHEMBL12210498 | 0.73 | HDAC6 (0.70) | HDAC6GRM5CYP4F2CYP4A11 | |
| SCHEMBL12335631 | 0.73 | NR1H2 (0.46) | HDAC6GRM5ALDH1A1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2011130163-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130163-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | HDAC6 1/4885GRM5 606/4885HPGD 1008/4885 |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | HDAC6 1/4885GRM5 606/4885HPGD 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.